Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Arcturus Therapeutics Holdings Inc (NQ: ARCT ) 20.61 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 20.61 Bid (Size) 17.00 (2) Ask (Size) 21.25 (14) Prev. Close 20.61 Today's Range 20.61 - 20.61 52wk Range 17.52 - 45.00 Shares Outstanding 26,562,951 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma September 13, 2024 From Arcturus Therapeutics Holdings Inc. Via Business Wire Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis September 03, 2024 From Arcturus Therapeutics Via Business Wire Performance YTD -37.72% -37.72% 1 Month -6.28% -6.28% 3 Month -24.59% -24.59% 6 Month -40.76% -40.76% 1 Year -21.49% -21.49% More News Read More Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences August 27, 2024 From Arcturus Therapeutics Holdings Inc. Via Business Wire ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q2 2024 August 05, 2024 Via InvestorPlace Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress August 05, 2024 From Arcturus Therapeutics Holdings Inc. Via Business Wire Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference August 01, 2024 From Arcturus Therapeutics Holdings Inc. Via Business Wire Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024 July 18, 2024 From Arcturus Therapeutics Holdings Inc. Via Business Wire Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs July 01, 2024 From Arcturus Therapeutics Holdings Inc. Via Business Wire Cathie Wood-Led Ark Invest Dumps $4.3M Worth Of Nvidia Shares Amid Rebound — Swoops Into Buy Stock Of This Netflix Rival June 25, 2024 Via Benzinga Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors June 20, 2024 From Arcturus Therapeutics Holdings Inc. Via Business Wire Cathie Wood-Led Ark Invest Sells $1.5M Worth Of Robinhood Shares Amid Muted Bitcoin Market — Also Dumps Zoom Stock Worth $3.3M June 12, 2024 Via Benzinga Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness June 10, 2024 Via Benzinga Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst June 07, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session June 07, 2024 Via Benzinga Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference June 07, 2024 From Arcturus Therapeutics Holdings Inc. Via Business Wire Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic May 28, 2024 Via Benzinga Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session May 28, 2024 Via Benzinga Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday May 28, 2024 Via Benzinga Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program May 28, 2024 From Arcturus Therapeutics Holdings Inc. Via Business Wire Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines May 22, 2024 From Achilles Therapeutics PLC Via GlobeNewswire Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine May 20, 2024 From Arcturus Therapeutics Via Business Wire Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences May 15, 2024 From Arcturus Therapeutics Holdings Inc. Via Business Wire Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential' May 09, 2024 Via Benzinga ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q1 2024 May 08, 2024 Via InvestorPlace Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress May 08, 2024 From Arcturus Therapeutics Holdings Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
